Lance Perry has joined the team at Quebec City-based Bodycad, where he is the new Vice President of Sales and Marketing.
New VP of Sales and Marketing at Bodycad – Lance Perry

“Lance has 25 years of experience in the orthopaedic industry, long involvement in R&D and marketing, strong surgeon relationships, and expertise in personalized orthopaedic design,” says Jean Robichaud, founder and CEO of Bodycad, in the January 30, 2017 news release. “Now, as a member of the Bodycad team, he will provide valuable insight and guidance on achieving our goal of personalizing orthopaedics.”
As indicated in the news release, “Throughout his career, he has had an ever-increasing conviction for patient specific orthopedics serving as the senior leader for many of Biomet’[s] and Zimmer-Biomets [sic] previous Patient Matched and Patient Specific Implant and Instrument initiatives. He joins Bodycad with a mission to make Personalized Orthopedics the unquestioned standard of care for today’s orthopedic patients.”
“I am excited to join the Bodycad team,” said Perry. “Personalized orthopaedics is a passion for me and I am excited to work with a company that has the same vision and the capabilities to make it a reality.”
Perry told OTW, “I am extremely energized by a key tenant of the Bodycad culture, ‘Listen to your customer!’ After an almost 18 month sabbatical, I am looking forward to reconnecting with the sales and surgeon community with the specific goal of achieving orthopedic perfection. My obvious bias is that this goal will only be achieved via implementation of numerous personalization initiatives ranging from patient specific implants and instruments to optimized efficiency in the planning, delivery and performance of the surgical intervention. I firmly believe that the imaging, software, and manufacturing capabilities that Bodycad continues to perfect will give us an advantage in today’s efficiency focused orthopedic environment.”

Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.